Bin-Chi Liao

1.1k total citations
36 papers, 791 citations indexed

About

Bin-Chi Liao is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Bin-Chi Liao has authored 36 papers receiving a total of 791 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 28 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Bin-Chi Liao's work include Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Research Studies (11 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Bin-Chi Liao is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Research Studies (11 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Bin-Chi Liao collaborates with scholars based in Taiwan, Singapore and United States. Bin-Chi Liao's co-authors include James Chih‐Hsin Yang, Chia‐Chi Lin, Jih‐Hsiang Lee, Chia‐Chi Lin, Jin‐Yuan Shih, Chao‐Chi Ho, Chong‐Jen Yu, Wei‐Yu Liao, Ya‐Fang Chen and Chin‐Hao Chang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Bin-Chi Liao

34 papers receiving 785 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bin-Chi Liao Taiwan 15 561 553 217 118 59 36 791
Ken Uchibori Japan 15 614 1.1× 567 1.0× 360 1.7× 156 1.3× 54 0.9× 59 885
Bernhard Heinrich Germany 14 187 0.3× 439 0.8× 160 0.7× 66 0.6× 33 0.6× 36 630
Giuseppina Rosaria Rita Ricciardi Italy 16 483 0.9× 588 1.1× 313 1.4× 293 2.5× 41 0.7× 42 947
Elvire Pons‐Tostivint France 13 351 0.6× 468 0.8× 238 1.1× 134 1.1× 11 0.2× 47 764
Anna Squadrilli Italy 11 394 0.7× 392 0.7× 220 1.0× 127 1.1× 22 0.4× 17 560
Dan Chan United States 6 194 0.3× 287 0.5× 250 1.2× 84 0.7× 24 0.4× 13 532
Santiago Ponce Aix Spain 15 406 0.7× 620 1.1× 165 0.8× 81 0.7× 24 0.4× 92 828
Tahsin M. Khan United States 8 364 0.6× 344 0.6× 275 1.3× 115 1.0× 22 0.4× 23 604
Elaine Shum United States 13 348 0.6× 388 0.7× 176 0.8× 69 0.6× 15 0.3× 52 586
Imane Chaib Spain 14 358 0.6× 309 0.6× 428 2.0× 199 1.7× 25 0.4× 39 719

Countries citing papers authored by Bin-Chi Liao

Since Specialization
Citations

This map shows the geographic impact of Bin-Chi Liao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bin-Chi Liao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bin-Chi Liao more than expected).

Fields of papers citing papers by Bin-Chi Liao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bin-Chi Liao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bin-Chi Liao. The network helps show where Bin-Chi Liao may publish in the future.

Co-authorship network of co-authors of Bin-Chi Liao

This figure shows the co-authorship network connecting the top 25 collaborators of Bin-Chi Liao. A scholar is included among the top collaborators of Bin-Chi Liao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bin-Chi Liao. Bin-Chi Liao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Zheng, Xin Fang, Feng Zhou, et al.. (2025). Implantable hydrogel-based scaffold integrating cascaded chemotherapy and self-amplified immunotherapy to suppress postsurgical tumor recurrence. Journal of Colloid and Interface Science. 700(Pt 2). 138475–138475. 1 indexed citations
2.
3.
Huang, Yenlin, Yi‐Ju Chen, Hsin-Yi Wu, et al.. (2024). The branched N-glycan of PD-L1 predicts immunotherapy responses in patients with recurrent/metastatic HNSCC. Oncogenesis. 13(1). 36–36. 1 indexed citations
4.
Liao, Bin-Chi, et al.. (2024). Locally advanced thymoma treated with lattice radiotherapy: a case report. 8. 8–8. 1 indexed citations
5.
Tan, Aaron C., D.-W. Kim, Gwo Fuang Ho, et al.. (2023). P2.10-03 Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study. Journal of Thoracic Oncology. 18(11). S352–S353.
6.
Lim, Wan‐Teck, Hsiang‐Fong Kao, Lisda Suteja, et al.. (2023). Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma. Nature Communications. 14(1). 2781–2781. 25 indexed citations
7.
Liao, Bin-Chi, Wei‐Hsun Hsu, Ching‐Yao Yang, et al.. (2023). Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Oncology. 102(4). 318–326. 5 indexed citations
8.
Kao, Hsiang‐Fong, Bin-Chi Liao, Yenlin Huang, et al.. (2022). Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis. Clinical Cancer Research. 28(8). 1560–1571. 53 indexed citations
9.
Li, Feng, Bin-Chi Liao, Ting Wang, Tingting Qi, & Yixin Wang. (2022). Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment. Frontiers in Pharmacology. 13. 918709–918709. 5 indexed citations
10.
Liao, Bin-Chi, et al.. (2021). CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer. Anticancer Research. 41(3). 1231–1242. 22 indexed citations
11.
Hsu, Chia‐Chi, Bin-Chi Liao, Wei‐Yu Liao, et al.. (2019). Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 15(1). 50–61. 61 indexed citations
12.
13.
Chang, Chin‐Chen, et al.. (2017). Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis. Medical Oncology. 34(8). 143–143. 20 indexed citations
14.
Liao, Bin-Chi, Jih‐Hsiang Lee, Chia‐Chi Lin, et al.. (2017). Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. Journal of the Formosan Medical Association. 117(4). 326–331. 11 indexed citations
15.
Liao, Bin-Chi, et al.. (2016). 151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs. Journal of Thoracic Oncology. 11(4). S123–S124. 1 indexed citations
16.
Liao, Bin-Chi, Chia‐Chi Lin, Jih‐Hsiang Lee, & James Chih‐Hsin Yang. (2016). Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Biomedical Science. 23(1). 86–86. 41 indexed citations
17.
Liao, Bin-Chi, Jih‐Hsiang Lee, Chia‐Chi Lin, et al.. (2015). Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. Journal of Thoracic Oncology. 10(12). 1754–1761. 138 indexed citations
18.
Liao, Bin-Chi, Chia‐Chi Lin, & James Chih‐Hsin Yang. (2015). Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Oncology. 27(2). 94–101. 118 indexed citations
19.
Liao, Bin-Chi, Yu‐Yun Shao, Ho‐Min Chen, et al.. (2014). Comparative Effectiveness of First-Line Platinum-Based Chemotherapy Regimens for Advanced Lung Squamous Cell Carcinoma. Clinical Lung Cancer. 16(2). 137–143. 13 indexed citations
20.
Liao, Bin-Chi, Chia‐Chi Lin, & James Chih‐Hsin Yang. (2013). First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments. Drugs. 73(4). 357–369. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ken Uchibori Breakdown of academic impact, for papers by Bernhard Heinrich Breakdown of academic impact, for papers by Giuseppina Rosaria Rita Ricciardi Breakdown of academic impact, for papers by Elvire Pons‐Tostivint Breakdown of academic impact, for papers by Anna Squadrilli Breakdown of academic impact, for papers by Dan Chan Breakdown of academic impact, for papers by Santiago Ponce Aix Breakdown of academic impact, for papers by Tahsin M. Khan Breakdown of academic impact, for papers by Elaine Shum Breakdown of academic impact, for papers by Imane Chaib
Rankless by CCL
2026